Inpefa (sotagliflozin) / Lexicon Pharma 
Welcome,         Profile    Billing    Logout  
 10 Diseases   12 Trials   12 Trials   1214 News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inpefa (sotagliflozin) / Lexicon Pharma
NCT05562063: Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients

Recruiting
4
60
US
Sotagliflozin, Placebo
Juan Badimon
Heart Failure With Preserved Ejection Fraction
11/25
01/26
PLUTO, NCT06147232: Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia

Not yet recruiting
4
69
Europe
Sotagliflozin, Inpefa (TM), Placebo
Steno Diabetes Center Copenhagen, Juvenile Diabetes Research Foundation, King's College London, Glostrup University Hospital, Copenhagen
Nephropathy, Diabetic Nephropathies, Diabetes Mellitus, Type 1, Albuminuria, Diabetic Complications Renal, Diabetic Complications Cardiovascular, Hypoxia
06/26
06/36
SOTATHROMBUS, NCT06618976: Antithrombotic Activities of Sotagliflozin vs. Empagliflozin

Not yet recruiting
4
16
US
Sotagliflozin, Empagliflozin
Icahn School of Medicine at Mount Sinai
Thrombosis
02/26
02/26
SONATA-HCM, NCT06481891: A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

Recruiting
3
500
US
Sotagliflozin, SAR439954/LX4211, Placebo
Lexicon Pharmaceuticals
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
07/26
08/26
SUGARNSALT, NCT06217302: Sotagliflozin to Slow Kidney Function Decline in Persons with Type 1 Diabetes and Diabetic Kidney Disease

Recruiting
3
150
Canada, US
Sotagliflozin, INPEFA, Placebo
Alessandro Doria, Canadian Institutes of Health Research (CIHR), The Kidney Foundation of Canada, The Cleveland Clinic, University of Michigan, University of Colorado, Denver, Northwestern University, Washington University School of Medicine, State University of New York - Upstate Medical University, Providence Medical Research Center, Stanford University, Montefiore Medical Center, University of Toronto, University Health Network, Toronto, University of Calgary, University of Alberta, University of British Columbia, Institut de Recherches Cliniques de Montreal, LMC Diabetes & Endocrinology Ltd., Joslin Diabetes Center, Lexicon Pharmaceuticals, DexCom, Inc., University of Washington, Breakthrough T1D
Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
12/28
05/29
2017-002309-36: Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients with Mild to Moderate Hypertension

Ongoing
2
40
Europe
Sotagliflozin, Jardiance, SAR439954, Film-coated tablet, Capsule, Jardiance
SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT, SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
Diabetes mellitus, Diabetes mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
START, NCT05405556: Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients

Recruiting
2
50
US
eGFR reporting
Martina McGrath, MD
Kidney Transplant
07/23
11/23
SOPHIST, NCT06435156: Sotagliflozin in Patients with Heart Failure Symptoms and Type 1 Diabetes

Not yet recruiting
2
320
NA
Sotagliflozin, Placebo
University of Dundee, Lexicon Pharmaceuticals, Juvenile Diabetes Research Foundation
Type 1 Diabetes, Heart Failure
06/26
06/26
ASPIRE, NCT06072326: Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation

Not yet recruiting
2
36
Europe, Canada, US
Sotagliflozin, Ambrisentan, Ambrisentan and Sotagliflozin
University Medical Center Groningen, Juvenile Diabetes Research Foundation, Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus With Diabetic Nephropathy
03/25
03/25
SOTA, NCT05696366: Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

Recruiting
1/2
24
US
Sotagliflozin, Volagidemab
University of California, San Diego, Lexicon Pharmaceuticals, Breakthrough T1D
Type 1 Diabetes
01/28
01/28
SOTA-CROSS HCM, NCT06433050: Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy

Not yet recruiting
1
26
NA
Sotagliflozin, Inpefa
University of Pennsylvania, National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy Without Obstruction
04/27
06/27
NCT06510894: Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression

Not yet recruiting
N/A
40
NA
Sotagliflozin, INPEFA
University of Pennsylvania, Duke University
Cardiac Sarcoidosis
12/26
12/27
Steno1, NCT06082063: Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Not yet recruiting
N/A
2000
NA
Aspirin tablet, Semaglutide, Sotagliflozin, Finerenone
Steno Diabetes Center Copenhagen, Aarhus University Hospital, Steno Diabetes Center Nordjylland, Steno Diabetes Center Odense, Slagelse Hospital, Nykøbing Falster County Hospital, Zealand University Hospital, Hillerod Hospital, Denmark, Rigshospitalet, Denmark, Hvidovre University Hospital, Regionshospitalet Viborg, Skive, Randers Regional Hospital, Herning Hospital, Hospital of South West Jutland, Regionshospitalet Silkeborg, Bispebjerg Hospital, Regionshospitalet Horsens
Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney Failure
02/29
01/30

Download Options